Skip to Main content Skip to Navigation
Journal articles

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Joseph Eron 1 Chloe Orkin 2 Douglas Cunningham 3 Federico Pulido 4 Frank Post 5 Stéphane De Wit 6 Erkki Lathouwers 7 Veerle Hufkens 7 John Jezorwski 8 Romana Petrovic 7 Kimberley Brown 7 Erika Van Landuyt 7 Magda Opsomer 7 E. Florence 9 M. Moutschen 10 E.Van Wijngaerden 11 I.Santos Gil J.De Vente 12 Linos Vandekerckhove 13 Bernard Vandercam 14 Jason Brunetta 15 Brian Conway 16 Marina Klein 17 Donald Murphy 18 Anita Rachlis 19 Stephen Shafran 20 Sharon Walmsley 21 Faiza Ajana 22 Laurent Cotte 23 P-M Girardy 24 Christine Katlama 25 Jean Michel Molina 26 Isabelle Poizot-Martin 27 Francois Raffi 28 David Rey 29 Jacques Reynes 30 Elina Teicher 31 Yazdan Yazdanpanah 32 Jacek Gasiorowski 33 Waldemar Halota 34 Andrzej Horban 35 Anna Piekarska 36 Adam Witor 37 Jose R Arribas 38 Ignacio Perez-Valero 38 Juan Berenguer 39 Jl Casado 40 Jose Gatell 41 Félix Gutiérrez 42 Maria-José Galindo 43 Maria del Mar Gutierrez 44 José Antonio Iribarren 45 Hernando Knobel 46 Eugenia Negredo 47 Juan Pineda 48 Daniel Podzamczer 49 J.Portilla Sogorb 4 C Ricart 50 Antonio Rivero 51 Ignacio Santos-Gil 52 Anders Blaxhült 53 Leo Flamholc 54 Magnus Gisslén 55 Anders Thalme 56 Jan Fehr 57 Andri Rauch 58 Marcel Stoeckle 59 Amanda Clarke 60 Brian Gazzard 61 Margaret Johnson 2 Andrew Ustianowski 62 Laura Waters 63 Justin R Bailey 64 Paul Benson 65 Laveeza Bhatti 66 Indira Brar 67 Ulf Bredeek 68 Cynthia Brinson 69 Gordon Crofoot 70 Edwin Dejesus 3 Craig Dietz 71 Robin Dretler 72 Franco Felizarta Carl Fichtenbaum 73 Joel Gallant Joseph Gathe Debbie Hagins Sarah Henn Wk Henry 74 Gregory Huhn Mamta Jain 75 Christopher Lucasti 76 Claudia Martorell 77 Cheryl Mcdonald 78 Anthony Mills 79 Javier Morales-Ramirez 80 Karam Mounzer 81 Ronald Nahass 82 Hannah Olivet 83 Olayemi Osiyemi 84 David Prelutsky 85 Moti Ramgopal 86 Bruce Rashbaum 87 Gary Richmond 88 Peter Ruane 89 Anthony Scarsella 90 Anita Scribner 91 Peter Shalit 92 David Shamblaw 93 Jihad Slim 94 Karen Tashima 95 Gene Voskuhl 96 Douglas Ward 97 Aimee Wilkin 98
1 UNC - University of North Carolina [Chapel Hill]
2 QMUL - Queen Mary University of London
3 Pueblo Family Physicians
4 UCM - Universidad Complutense de Madrid = Complutense University of Madrid [Madrid]
5 KCH - King's College Hospital
6 ULB - Université libre de Bruxelles
7 Janssen Pharmaceutica [Beerse]
8 Janssen Research & Development
9 ITM - Institute of Tropical Medicine [Antwerp]
10 University Liege - Department of Infectious and Parasitic Diseases
11 KU Leuven - Catholic University of Leuven - Katholieke Universiteit Leuven
12 Living Hope Foundation
13 Ghent University Hospital
14 Cliniques Universitaires Saint-Luc [Bruxelles]
15 Maple Leaf Clinic
16 Vancouver Infectious Diseases Centre
17 McGill University = Université McGill [Montréal, Canada]
18 University of Toronto
19 Sunnybrook Health Sciences Centre
20 University of Alberta
21 University Health Network
22 Services des maladies infectieuses [Tourcoing]
23 Hôpital de la Croix-Rousse [CHU - HCL]
24 SU - Sorbonne Université
25 CHU Pitié-Salpêtrière [AP-HP]
26 Service de maladies infectieuses et tropicales [Saint-Louis]
27 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
28 CHU Nantes - Centre hospitalier universitaire de Nantes
29 CHU Strasbourg
30 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
31 Service de Maladies Infectieuses et Tropicales [CHU Bicêtre]
32 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
33 UWr - University of Wrocław [Poland]
34 Faculty of Medicine [Bydgoszcz, Poland]
35 Medical University of Warsaw - Poland
36 MUL - Medical University of Łódź
37 Regional Hospital [Chorzow, Poland]
38 La Paz Hospital, IdiPAZ
39 Hospital General Universitario "Gregorio Marañón" [Madrid]
40 Hospital Universitario Ramón y Cajal [Madrid]
41 Infectious Diseases Service, AIDS Research Group, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain.
42 Hospital Universitario de Elche
43 Hospital Universitario de Valencia
44 Hospital de la Santa Creu i Sant Pau
45 Donostia Hospital Universitario San Sebastian
46 IMIM-Hospital del Mar
47 LLuita contra la Sida Fdn-HIV Unit, Germans Trias i Pujol University Hospital- Universitat Autònoma de Barcelona
48 Hospital Universitario de Valme
49 Hospital Universitari de Bellvitge
50 UV - Universitat de València
51 Hospital Universitario Reina Sofía
52 Hospital La Princesa, Madrid
53 Karolinska Institutet, Södersjukhuset
54 Skane University Hospital [Malmo]
55 GU - University of Gothenburg
56 Karolinska University Hospital [Stockholm]
57 University hospital of Zurich [Zurich]
58 Inselspital - Bern University Hospital [Berne]
59 University Hospital Basel [Basel]
60 Royal Sussex County Hospital
61 Chelsea and Westminster Hospital
62 North Manchester General Hospital
63 UCL - University College of London [London]
64 Johns Hopkins University School of Medicine [Baltimore]
65 Be Well
66 AIDS healthcare foundation [California]
67 Henry Ford Hospital
68 Metropolis Medical
69 Central Texas Clinical Research
70 The Crofoot Research Center
71 Orlando Immunology Center
72 Kansas City Free Health Clinic
73 UC - University of Cincinnati
74 University of Minnesota System
75 University of Texas Southwestern Medical Center
76 South Jersey Infectious Disease
77 Infectious Disease
78 Tarrant County Infectious Disease Associates
79 Southern California Men’s Medical Group
80 Clinical Research Puerto Rico Inc
81 Philadelphia FIGHT
82 ID care
83 Community Research Initiative of New England
84 Triple O Research Institute PA
85 Washington University School of Medicine in St. Louis
86 Midway Immunology Center
87 Capital Medical Associates
88 Broward General Medical Center
89 Ruane Clinical Research Group
90 Pacific Oaks Medical Group
91 DCOL Center for Clinical Research
92 Peter Shalit MD and Associates
93 La Playa Medical Group
94 Seton Hall University
95 Warren Alpert Medical School of Brown University
96 AIDS Arms, Inc
97 Dupont Circle Physicians Group
98 Wake Forest School of Medicine [Winston-Salem]
Abstract : Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed viral load [VL] ≥50 copies/mL) and VL < 50 copies/mL (virologic suppression) and ≥50 copies/mL (VF) (FDA-snapshot analysis). Of 1141 randomized patients, 1080 continued in the extension phase. Few patients had PDVR (D/C/F/TAF: 3.1%, 24/763 cumulative through week 96; late-switch: 2.3%, 8/352 week 52–96). Week 96 virologic suppression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch). VF was 1.2% and 1.7%, respectively. No darunavir, primary PI, tenofovir or emtricitabine resistance-associated mutations were observed post-baseline. No patients discontinued for efficacy-related reasons. Few discontinued due to adverse events (2% D/C/F/TAF arm). Improved renal and bone parameters were maintained in the D/C/F/TAF arm and observed in the late-switch arm, with small increases in total cholesterol/high-density-lipoprotein-cholesterol ratio. A study limitation was the lack of a control arm in the week 96 analysis. Through 96 weeks, D/C/F/TAF resulted in low PDVR rates, high virologic suppression rates, very few VFs, and no resistance development. Late-switch results were consistent with D/C/F/TAF week 48 results. EMERALD week 96 results confirm the efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF.
Keywords : Switch study Darunavir/cobicistat/emtricitabine/TAF Single-tablet regimen Safety Efficacy
Document type :
Journal articles
Complete list of metadata

Cited literature [38 references]  Display  Hide  Download
https://hal-amu.archives-ouvertes.fr/hal-02615274
Contributor : Administrateur Hal Amu Connect in order to contact the contributor
Submitted on : Friday, May 22, 2020 - 1:19:27 PM
Last modification on : Tuesday, December 7, 2021 - 10:12:30 AM

File

Vignette du document
1-s2.0-S0166354219302475-main ...
Publication funded by an institution

Licence

Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Collections

UNIV-AMU | HCL | IRD | U1252 | INSERM | SORBONNE-UNIVERSITE | SU-TI

Citation

Joseph Eron, Chloe Orkin, Douglas Cunningham, Federico Pulido, Frank Post, et al.. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Research, Elsevier Masson, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩. ⟨hal-02615274⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Les métriques sont temporairement indisponibles